Search results for "Health Care Costs"

showing 10 items of 43 documents

Osteoporosis: Economic Burden of Disease in Italy.

2020

Background and Objective: Today, osteoporosis is the most common bone disease and an important public health problem in all developed countries. The objective of this study was to estimate the costs associated with the management and treatment of osteoporosis in order to assess the economic burden in Italy for 2017, in terms of direct medical costs and social security costs. Methods: A cost of illness model was developed to estimate the average cost per year sustained by the NHS (National Health Service) and Social Security System in Italy. A systematic literature review was performed to obtain epidemiological, direct and indirect costs parameters where available. Hospitalisation costs were…

Patient Discharge.Malemedicine.medical_specialtySettore SECS-P/06accountingalliedhealth030204 cardiovascular system & hematology030226 pharmacology & pharmacyState MedicineServizio Sanitario Nazionale03 medical and health sciencesIndirect costs0302 clinical medicineCost of IllnessInternational Classification of DiseasesEnvironmental healthEpidemiologyInternational Classification of DiseasemedicineHumansPharmacology (medical)health care economics and organizationsAverage costAgedPensionbusiness.industryPublic healthOsteoporosieconomicsAged; Female; Health Care Costs; Hospitalization; Humans; International Classification of Diseases; Italy; Male; Middle Aged; Osteoporosis; Patient Discharge; State Medicine; Cost of IllnessGeneral MedicineHealth Care Costsosteoporosi Italia Servizio Sanitario NazionaleMiddle AgedItaliaPatient DischargeHealth Care CostSocial securityHospitalizationSystematic reviewItalySettore MED/42OsteoporosisFemalebusinessDeveloped countryHumanClinical drug investigation
researchProduct

Cost-Effectiveness Analysis: Stress Ulcer Bleeding Prophylaxis with Proton Pump Inhibitors, H2 Receptor Antagonists

2012

Abstract Objectives Proton pump inhibitors (PPIs) and H2-receptor antagonists (H2RAs) present varying pharmacological efficacy in preventing stress ulcer bleeding (SUB) in intensive care units. The literature also reports disparate rates of ventilator-assisted pneumonia (VAP) as side effects of these treatments. We compared the cost-effectiveness of these two prophylactic pharmacological options. Methods We constructed a decision tree with a 60-day time horizon for patients at high risk for developing SUB, receiving either PPIs or H2RAs. For each treatment strategy, patients could be in one of three states of health: SUB, VAP, or no complication. Contemporary, clinically relevant probabilit…

Peptic Ulcermedicine.medical_specialtyMultivariate analysisDatabases FactualCost effectivenessmedicine.drug_classCost-Benefit AnalysisMEDLINEProton-pump inhibitorH2RAIntensive careInternal medicinemedicineHumanscost-effectivenessbusiness.industryHealth PolicyStress ulcerDecision TreesPublic Health Environmental and Occupational HealthProton Pump InhibitorsHealth Care CostsCost-effectiveness analysisLength of StayAnti-Ulcer Agentsmedicine.diseaseUnited StatesSurgerystress ulcer bleedingHistamine H2 AntagonistsMultivariate AnalysisGastrointestinal HemorrhagebusinessComplicationValue in Health
researchProduct

Economic evaluation of sublingual immunotherapy vs. symptomatic treatment in allergic asthma.

2009

Background The worldwide increased prevalence of allergic diseases, and especially of respiratory allergy, is paralleled by increased health costs. This requires consideration of the cost to efficacy ratio of the available treatment to identify the optimal choice. Objective To compare the different economic relevance, over a long evaluation time, of symptomatic pharmacologic therapy and sublingual immunotherapy (SLIT) in patients with allergic asthma. Methods Seventy patients with perennial allergic asthma, sensitized to dust mites, were enrolled; 50 of these patients were treated with SLIT against house dust mites and 20 were treated with symptomatic drugs. The patients were evaluated for …

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyAllergyAdolescentCost-Benefit AnalysisImmunologyPopulationAdministration SublingualFollow-Up StudieSublingual administrationDrug TherapyImmunopathologyInternal medicinemedicineImmunology and AllergyHumansCost-Benefit AnalysieducationChildAsthmaeducation.field_of_studyDrug Therapy; Combined Modality Therapy; Immunotherapy; Humans; Asthma; Child; Health Care Costs; Cost-Benefit Analysis; Adult; Middle Aged; Follow-Up Studies; Adolescent; Administration Sublingual; Male; Femalebusiness.industryRespiratory diseaseHealth Care CostsMiddle Agedmedicine.diseaseSlitCombined Modality TherapyAsthmaSurgeryHealth Care CostObservational studyFemaleImmunotherapybusinessHumanFollow-Up StudiesAnnals of allergy, asthmaimmunology : official publication of the American College of Allergy, Asthma,Immunology
researchProduct

Economic costs associated with acute attacks and long-term management of hereditary angioedema.

2010

Background Hereditary angioedema (HAE) is a rare autosomal dominant disorder characterized by recurrent acute attacks of swelling of the larynx, abdomen, and periphery. Objective To assess the economic burden associated with acute attacks and long-term management of HAE. Methods Burden was assessed via a Web-based survey of HAE patients (≥18 years old) that solicited information on attack characterization, short-term treatment, long-term disease management, impact on work, and patient costs. A standardized instrument, the Work Productivity and Activity Impairment questionnaire, was included to assess impact on work productivity. Standard medical costs and US average wage costs were assigned…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyEmergency Medical Servicesmedia_common.quotation_subjectImmunologyWageDrug CostsIndirect costsCost of IllnessEconomic costSurveys and QuestionnairesLong term managementmedicineImmunology and AllergyHumansDisease management (health)Hospital CostsProductivityhealth care economics and organizationsmedia_commonbusiness.industryAngioedemas HereditaryEmergency departmentHealth Care Costsmedicine.diseaseHospitalizationHealth Care SurveysEmergency medicineHereditary angioedemaAcute DiseasePhysical therapyFemalebusinessAnnals of allergy, asthmaimmunology : official publication of the American College of Allergy, Asthma,Immunology
researchProduct

Informal caregiving burden in advanced non-small cell lung cancer: the HABIT study.

2007

Introduction This study's aim was to assess economic data regarding the home assistance burden for advanced non-small cell lung cancer (NSCLC) patients in Italy. Patients and Methods One hundred four NSCLC patients in second-line chemotherapy (2LC) or in supportive therapy (ST) were enrolled in 18 Italian oncology departments and were observed for 3 months. The main caregiver's workload was assessed monthly by a task scale; other caregivers' activities were also registered. Eastern Cooperative Oncology Group performance status was assessed by physicians, and patients completed the Lung Cancer Symptoms (LCS) subscale. Formal caregiving time was valued according to market prices; informal car…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyLung NeoplasmsHome Nursingmedia_common.quotation_subjectAntineoplastic Agentscaregiving burden in advanced non-small cell lung cancerNSCLCQuality of lifeCost of IllnessCarcinoma Non-Small-Cell LungmedicineHumansLung cancermedia_commonAgedAged 80 and overbusiness.industrySocial SupportWorkloadAssistance burdenHealth Care CostsMiddle Agedmedicine.diseaseOncologyCaregiversItalySocioeconomic FactorsInformal caregivingSpouseSupportive psychotherapyScale (social sciences)Family medicinePhysical therapyCosts and Cost AnalysisQuality of LifeFemaleHabitNon small cellbusiness
researchProduct

Healthcare costs of the SATisfaction and adherence to COPD treatment (SAT)study follow-up

2019

Abstract Background Chronic obstructive pulmonary disease (COPD) is characterised by recurring exacerbations. We estimated the costs of healthcare resources for COPD management funded by the Italian National Healthcare Service (INHS) for one year. Methods We examined the demographic, clinical, and economic variables at enrolment and follow-up visits (at 6 and 12 months) of COPD patients participating in the SAT study and referred to 20 Italian pulmonary centres with different institutional characteristics. Costs were expressed in Euro (€) 2018. A random effects log-linear panel regression model was performed to predict the average cost per patient. Results Most of the centres were public in…

Pulmonary and Respiratory MedicineAdultmedicine.medical_specialtyCost-Benefit AnalysisSocio-culturaleMuscarinic AntagonistsPersonal SatisfactionSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineHealth careMedicineHumansCOPD management Econometric model Healthcare costs030212 general & internal medicineAdrenergic beta-2 Receptor AgonistsAverage costAgedAged 80 and overCOPDbiologyCOPD management; Econometric model; Healthcare costsbusiness.industryCOPD managementOxygen Inhalation TherapyRegression analysisHealth Care CostsLamaMiddle AgedHealthcare costsbiology.organism_classificationmedicine.diseaseRandom effects modelBronchodilator AgentsPatient Care ManagementRespiratory Function TestsEconometric model030228 respiratory systemItalyEmergency medicinePublic universityDisease ProgressionPatient ComplianceDrug Therapy CombinationbusinessPanel dataFollow-Up Studies
researchProduct

Economic burden of low physical activity and high sedentary behaviour in Finland

2022

BackgroundLow physical activity and high sedentary behaviour are unquestionably relevant for public health while also increasing direct and indirect costs.MethodsThe authors examined the direct and indirect costs attributable to low physical activity and high sedentary behaviour in Finland in 2017. Costs related to major non-communicable diseases drawn from Finnish registries covered direct costs (outpatient visits, days of inpatient care, medication and institutional eldercare) and indirect costs (sickness-related absences, disability pensions, unemployment benefits, all-cause mortality and losses of income tax revenue). Prevalences of low physical activity and high sedentary behaviour (≥8…

kuolleisuusAdultAdolescentEpidemiologyFinancial Stressliikuntaterveystaloustiedesairauspoissaolotistuminentaloudelliset vaikutuksetCost of IllnesstartuntatauditterveysvaikutuksetHumansExerciseFinlandhealth care economics and organizationsAgedsairastavuusPublic Health Environmental and Occupational HealthliikkumattomuusHealth Care Costs3142 Public health care science environmental and occupational healthkustannuksettyökyvyttömyyseläkkeetSedentary Behaviorfyysinen aktiivisuustyökyvyttömyysJournal of Epidemiology and Community Health
researchProduct

Cost Effectiveness of Peginterferon ??-2a Plus Ribavirin versus Interferon ??-2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepati…

2004

Introduction: In adults with previously untreated chronic hepatitis C (CHC), the combination of peginterferon α-2a plus ribavirin produces a higher rate of sustained virological response (SVR) than interferon α-2b plus ribavirin, but it is still unproven whether this increase is cost effective. The objective of this study was to determine if the gain in SVR with peginterferon α-2a plus ribavirin is worth the incremental cost. Methods: We constructed a Markov model of disease progression in which cohorts of patients received peginterferon α-2a plus ribavirin or interferon α-2b plus ribavirin for 48 weeks (hepatitis C virus [HCV] genotype 1 and non-1 patients with fibrosis) or 24 weeks (genot…

medicine.medical_specialtyCirrhosisGenotypeCost effectivenessCost-Benefit AnalysisHepatitis C virusInterferon alpha-2medicine.disease_causeAntiviral AgentsSensitivity and SpecificityGastroenterologypeginterferon alpha2aPolyethylene Glycolschemistry.chemical_compoundchronic hepatitiInterferonInternal medicineRibavirinmedicineHumansRandomized Controlled Trials as Topicalpha2b interferonAntiviral AgentPharmacologybusiness.industryHealth PolicyRibavirinPublic Health Environmental and Occupational HealthInterferon-alphavirus diseasesHealth Care CostsHepatitis CHepatitis C Chronicmedicine.diseaseMarkov ChainsRecombinant Proteinsdigestive system diseasesModels EconomicTreatment OutcomechemistryImmunologyQuality of LifePeginterferon alfa-2bDrug Therapy CombinationbusinessPeginterferon alfa-2amedicine.drugPharmacoEconomics
researchProduct

Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Socie…

2020

This is a pre-copyedited, author-produced version of an article accepted for publication in European Journal of Preventive Cardiology following peer review. The version of record Piepoli, M.F., Abreu, A., Albus, C., Ambrosetti, M., Brotons, C., Catapano, A.L. ... Tiberi, M. (2020). Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Society of Cardiology*. European Journal of Preventive Cardiology (EJPC), 27(2), 181-205 is available online at: https://doi.org/10.1177/2047487319893035. European guidelines on cardiovascular prevention in clinical practice were first published in 1994 and have been regu…

medicine.medical_specialtyConsensusEpidemiologyCost effectivenessCost-Benefit AnalysisPopulationCardiologyPsychological interventionphysical activitypopulationGuidelinesrisk managementsmokingrehabilitationlipidsprimary carepreventionhealthy lifestyleInternal medicinePreventive Health ServicesEpidemiologyHumansMedicineguidelineseducationpsychosocial factorsstakeholderRisk managementeducation.field_of_studyVDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin sosialmedisin: 801diabetesbusiness.industryStakeholderblood pressurerisk assessmentHealth Care CostsProtective FactorsPrognosisnutritionCardiovascular DiseasesHeart Disease Risk FactorsCardiologyPosition paperCardiology and Cardiovascular MedicinebusinessRisk assessmentclinical settings
researchProduct

Prevention of eating disorders-Efficacy and cost-benefit of a school-based program ("MaiStep") in a randomized controlled trial (RCT).

2021

Objective Given the severity of eating disorders, effective and easily implementable prevention programs which reduce incidence rates and in addition have health-economic benefits are essential. The majority of research on prevention programs focuses on questionnaire-based efficacy or the reduction of eating disorder symptoms while neglecting the health-economic perspective. By contrast, the present study focuses on both an efficacy analysis considering diagnostic criteria (DSM-5) and on evaluating the cost-benefit of a universal prevention program for eating disorders ("MaiStep"). Method A three-arm randomized controlled trial with baseline, posttreatment and 12-month follow-up was conduct…

medicine.medical_specialtySchoolsAdolescentbusiness.industryBulimia nervosaCost-Benefit AnalysisHealth Care Costsmedicine.diseaseDSM-5law.inventionClinical trialFeeding and Eating DisordersPsychiatry and Mental healthEating disordersRandomized controlled triallawIntervention (counseling)Relative riskHealth carePhysical therapyMedicineHumansbusinessStudentsThe International journal of eating disordersREFERENCES
researchProduct